Wolverine (BPC-157 + TB-500) Research Summary

Research Library Summary — PHX Performance Research

For laboratory research use only. Not for human consumption. This summary describes published research and is not medical advice.

What the Research Suggests, in Plain Language

“Wolverine” is a name for BPC-157 and TB-500 used together. Almost no research has tested the two together.

• In animal studies, one 2026 rat experiment on injured Achilles tendons tested BPC-157, TB-500 and both together. In that study, tendon tissue looked better under the microscope in the TB-500 group and in the combination group than in untreated rats. Only the TB-500-alone group showed a clear difference in tendon strength.

• That single study did not show that the two together work better than either one alone.

• No study has tested the combination in people, and no safety studies of the combination exist.

In short: research on this blend is limited to one animal study and to separate research on each ingredient. It does not show that the combination is safe or effective in people.

Overview

Wolverine refers to a combination of BPC-157 and TB-500. Both are short synthetic peptides. The combination is not an approved product. No clinical trials of the combination are identified.

What the Research Actually Presents

Individual peptides:

• BPC-157 (pentadecapeptide): Large animal literature (primarily rats from one Croatian group) reports observations consistent with tissue recovery in tendon, ligament, muscle, gastrointestinal, and vascular injury models. Human data are limited to three small uncontrolled pilots rated very low certainty by a 2026 systematic review.

• TB-500 (synthetic fragment of thymosin beta-4): Most human clinical data concern full-length thymosin beta-4 (Tβ4) candidates rather than the synthetic fragment. Animal studies report tissue-repair-related observations in wound, cardiac, and other models. Essentially no human efficacy data exist for the synthetic TB-500 fragment itself.

Combination study:

• One 2026 rat Achilles tendon study (PMID 42542926): Both the TB-500 group and the BPC-157 + TB-500 group showed significantly better histology (tissue-structure) scores than controls. Load-to-failure was significant only in the TB-500-alone group.

Remaining catalog entries are 2025–2026 reviews that discuss the components separately, including one titled “Dangers of Injectable Peptides and Other Unregulated ‘Biohacking’ Drugs” (PMID 42757290). No human studies of the combination exist.

What the Research Suggests

Each peptide has its own preclinical literature (animal models for both; very limited human pilots for BPC-157 only).

One rat tendon study reported better histology scores with the combination versus controls in that model. The study did not demonstrate clear synergistic effects beyond what was observed with the individual peptides.

No human data on the combination exist. Any suggestion of combined effects is limited to a single animal study.

Mechanism and Signaling Pathways (as described in the literature)

BPC-157 animal studies describe growth-factor and nitric-oxide pathway observations in injury models. TB-500/Tβ4 literature describes actin-binding and cell-migration effects in preclinical models. No dedicated mechanism studies of the combination exist beyond the single rat tendon study.

Research Landscape

Catalog: 14 records — 0 human randomized controlled trials (RCTs), 2 other human, 1 animal, 0 in-vitro, 10 reviews, 0 systematic reviews/meta-analyses, 1 other. Almost all entries discuss the individual components.

Key Studies

• Biçer O et al. 2026: animal study (rats), Achilles tendon injury model; BPC-157, TB-500 and the combination compared with controls (PMID 42542926).

• Moiz A et al. 2026: review of risks of unregulated injectable peptides, including BPC-157 and TB-500 (PMID 42757290).

• Poolton JT et al. 2026: systematic review of human BPC-157 evidence, certainty rated very low (PMID 42885452).

Safety Findings Reported in the Studies

No safety studies of the combination are identified.

Limitations and Evidence Gaps

No human data on the combination. Only one animal study of the blend. Evidence is otherwise limited to the individual peptides.

Regulatory Status

Combination is not an approved product. See individual BPC-157 and TB-500 entries.

References

Biçer O et al. 2026 (PMID 42542926, rat Achilles combination study). Moiz A et al. 2026 (PMID 42757290). Poolton JT et al. 2026 (PMID 42885452). Individual peptide literature is detailed in the BPC-157 and TB-500 summaries.

Evidence reviewed through November 2026 (PHX research catalog snapshot of PubMed, ClinicalTrials.gov and Europe PMC).

For laboratory research use only. Not for human consumption. This summary describes published research and is not medical advice.